EICHORCondition: Crohn's Disease · Sponsor: Celularity Incorporated
This Phase 2a study evaluated the efficacy, safety, and tolerability of intravenous human placenta-derived cells (PDA001) compared with placebo in adults with moderate-to-severe Crohn's disease. Three PDA001 dose levels were evaluated.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Cedars Sinai Medical Center | Los Angeles, California, United States | — |
| University of California, Irvine | Orange, California, United States | — |
| Yale School of Medicine Digestive Diseases | New Haven, Connecticut, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Indiana University | Indianapolis, Indiana, United States | — |
| Mt Sinai Hospital | New York, New York, United States | — |
| Rochester General Hospital | Rochester, New York, United States | — |
| Stony Brook University | Stony Brook, New York, United States | — |
| Case Western Reserve University | Cleveland, Ohio, United States | — |
| Vanderbilt University | Nashville, Tennessee, United States | — |
| Baylor College of Medicine | Houston, Texas, United States | — |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01155362